维昇药业-B2025中期报告

维 昇 药 业 股份代號 : 2561（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 2025中期報告 2 4 5 19 29 30 31 33 34 35 47 Michael J CHANG2025827 97927 YAO Zhengbin (Bing)2025827 2920 YAO Zhengbin (Bing)20258272025827 International Corporation Services Ltd.Harbour Place2nd FloorPO Box 472103 South Church StreetGrand CaymanKY1-1106Cayman Islands YAO Zhengbin (Bing) 69B33-108 33191919 8235 International Corporation Services Ltd.Harbour Place2nd FloorPO Box 472103 South Church StreetGrand CaymanKY1-1106Cayman Islands 28833200041 183171712-1716 15153 2561 https://www.visenpharma.com 201811(lonapegsomatropin)PGHD183(lonapegsomatropin)(palopegteriparatide)(navepegritide)C (i)PGHD(lonapegsomatropin)3BLA2024118202437BLA(ii)(palopegteriparatide)320231(iii)(navepegritide)2 (1)20224(lonapegsomatropin)PGHD32024118PGHDBLA202437(2)20231(palopegteriparatide)3(3)(navepegritide)220231120244(4) (lonapegsomatropin) (lonapegsomatropin)331 75 2(lonapegsomatropin)52AHV3(lonapegsomatropin)201811AscendisPharma(lonapegsomatropin)(lonapegsomatropin)-1(lonapegsomatropin) PGHD(lonapegsomatropin)BLA202437 202512025521 2025PGHDBLA 2024420254 • (lonapegsomatropin)Ascendis Pharma 202310Ascendis Pharma2025612AscendisPharma (lonapegsomatropin)CDMO20237AscendisPharmaAscendisPharma202312CDMO2025620252027 DCDDCDDCDDCDBLA2028 202536enliGHtenHormoneResearch in PaediatricsDOI:10.1159/000545064(lonapegsomatropin)6 2025728AscendisPharma(FDA)SKYTROFA®lonapegsomatropin-tcgdTransConhGH(GHD) (lonapegsomatropin)2025BLA GSP202482025619 (lonapegsomatropin)2025714202581481624 18A.08(3)(lonapegsomatropin) (palopegteriparatide) (palopegteriparatide)201811AscendisPharma(palopegteriparatide)(palopegteriparatide)24(palopegteriparatide)320231 320253 (palopegteriparatide)20257(palopegteriparatide)2025 • 2025512AscendisPharma22144(palopegteriparatide) 2025714AscendisPharmaPaTHway31563(palopegteriparatide) 18A.08(3)(palopegteriparatide) (navepegritide) • (navepegritide)210201811AscendisPharma(navepegritide)(navepegritide)(navepegritide)2 • 2025512(navepegritide)25252 20258241042(navepegritide)52AGV100μgCNP/kg(navepegritide)AGV5.939(P=0.018)4.760100μg/kg(navepegritide)104ACHZ0.051040.199(navepegritide)Ascendis Pharma2 • 202562AscendisPharmaFDA(navepegritide)NDAPDUFA20251130 2 0 2 569A s c e n d i sP h a r m aC O A C H2 6( n a v e p e g r i t i d e )(lonapegsomatropin) 18A .08(3)(navepegritide) 20256308.0620246.0220253213.002026 20255252020 20256303142%15 46.6 AscendisPharma58564(lonapegsomatropin)313 (lonapegsomatropin)AscendisPharma(lonapegsomatropin)964(lonapegsomatropin)2037928 (navepegritide)AscendisPharma(navepegritide)16182040210 (palopegteriparatide)AscendisPharma(palopegteriparatide)20232040619 AscendisPharma1392038629 3132034424 維藥業127401www.visenpharma.com1 202563054 202563066.3202463055.5 2025630 ••••(TransCon)•• 18A.08(3) 20246307.226.9%20256305.320246302.91.0 20246301.620256307.1 202463038.97.719.8%202563046.6 202463043.637.6%202563060.0(i)(ii) 2024202563090,00039,000 202420256309.79.6 202463083.541.4%2025630118.0 20256302025630108.72025630805.920241231203.6 2025630 2025630 2025630 202563020241231 202412314.3202563023.0 2025630 2025630100% 202563020241231 2025630831.420241231170.4661.0 202563020256305% 2025630 20256302024630 C1 20256302 2F.1.3 2F.1.3MichaelWolffJENSEN20256272025 3.213.22D.3YAOZhengbin(Bing)20258272025827 20256302410 Michael Wolff JENSENJan Møller MIKKELSEN2025627Michael Wolff JENSEN MichaelJ.CHANG202582720258272025827 13.51B(1) 13.2013.2113.22 XV352 1.VPPTrustVPP TrustTricor Equity Trustee LimitedTricor Equity Trustee LimitedVPPLU Limited XVXV78352 20256303365% 1.(i) Ascendis Pharma Endocrinology Division20,568,182(ii) Ascendis PharmaGrowthDisorders7,713,068(iii)Ascendis Pharma Bone Diseases12,855,114Ascendis Pharma Endocrinology DivisionAscendis Pharma Growth DisordersAscendis Pharma Bone DiseasesAscendisPharma A/SAscendis Pharma A/SAscendisPharma Endocrinology DivisionAscendis Pharma Growth DisordersAscendis Pharma Bone Diseases 2.VivoPlenilune IX LimitedVivoCapital37,167,064Vivo Plenilune IXLimitedVivo Capital Fund IX (Cayman), L.P.Vivo Capital Fund IX (Cayman), L.P.Vivo Capital IX (Cayman), LLC.Vivo Capital IX (Cayman), LLC.Vivo CapitalFund IX (Cayman), L.P.Vivo Plenilune IX Limited 3.(L) 4.113,926,864 336 20194292021182021310 (i)(ii)(iii)(iv)D. 238,845,5005,000,000VPP LU Limited3,845,500VP EIP NUS LIMITEDVP EIP US LIMITED 0 (1). (4). *2025321202511 20221116 10,659,5009.4%2025382,399,5002.1% 3% D.20241231 2025612435,00020256272025612 2,399,5001,964,50071,9850.40% 1.202620291125%2.2025612* 2025321672.3620.2 202563044.8 維藥業 2025827 Ernst & Young27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong ⭰㰟㛪姯⸒Ṳ⋀㈧榀㸖毩歁㵳勘䙮怺979噆⤑⏋✱ᷧ⺎27㧺Tel曢婘: +852 2846 9888Faxₚ䜆: +852 2868 4432ey.com 維藥業 3046維藥業2025630343434 2410 34 2025827 2025年6月30日 1. 維藥業2018111P.O. Box 472, Harbour Place, 2nd Floor, 103 South Church Street, George Town, G